Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1992-12-4
|
| pubmed:abstractText |
We analysed 99 courses of leukapheresis after the use of cytotoxic drugs or cytotoxic drugs plus G-CSF (cytotoxic/G-CSF) to mobilize peripheral blood stem cells (PBSC) in 68 patients with hematologic or solid malignancies. Mean yields of granulocyte-macrophage progenitor cells (CFU-GM) with cytotoxic/G-CSF mobilization were significantly higher than those with cytotoxic mobilization (18.6 vs 8.40 x 10(4)/kg). The optimal timing of collection was different between these two mobilizations; the mean number of days to a peak level of circulating CFU-GM after cytotoxic/G-CSF mobilization was less than that after cytotoxic mobilization (24.2 vs 27.7 days). The leukocyte level on the day of peak CFU-GM was significantly higher in cytotoxic/G-CSF mobilization than that in cytotoxic mobilization (mean 12.8 vs 2.7 x 10(9)/l), whereas the platelet level was not different (mean 132 vs 125 x 10(9)/l). Increasing patient age was not a major adverse factor for PBSC collection. Synchronous recovery of both leukocytes and platelets was critical for achieving a high CFU-GM yield in these two mobilizations. Following PBSC autotransplantation, the rate of trilineage hematologic reconstitution showed a significant correlation with the infused dose of CFU-GM, whether they were collected with cytotoxic or cytotoxic/G-CSF mobilization. These results suggest that G-CSF can expand the PBSC pool and that CFU-GM yield after cytotoxic/G-CSF mobilization may predict trilineage hemopoietic reconstitution after ABSCT, as well as cytotoxic mobilization.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0268-3369
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
10
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
215-20
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:1384898-Adolescent,
pubmed-meshheading:1384898-Adult,
pubmed-meshheading:1384898-Antineoplastic Agents,
pubmed-meshheading:1384898-Blood Cells,
pubmed-meshheading:1384898-Bone Marrow Transplantation,
pubmed-meshheading:1384898-Child,
pubmed-meshheading:1384898-Child, Preschool,
pubmed-meshheading:1384898-Colony-Forming Units Assay,
pubmed-meshheading:1384898-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:1384898-Hematopoiesis,
pubmed-meshheading:1384898-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:1384898-Hematopoietic Stem Cells,
pubmed-meshheading:1384898-Humans,
pubmed-meshheading:1384898-Infant,
pubmed-meshheading:1384898-Leukapheresis,
pubmed-meshheading:1384898-Leukemia,
pubmed-meshheading:1384898-Leukocyte Count,
pubmed-meshheading:1384898-Lymphoma, Non-Hodgkin,
pubmed-meshheading:1384898-Middle Aged,
pubmed-meshheading:1384898-Neoplasms,
pubmed-meshheading:1384898-Transplantation, Autologous
|
| pubmed:year |
1992
|
| pubmed:articleTitle |
Cytotoxic drug and cytotoxic drug/G-CSF mobilization of peripheral blood stem cells and their use for autografting.
|
| pubmed:affiliation |
First Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't
|